Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
September 6, 2004
- Iressa Shows 5.81% Incidence of Interstitial Pneumonia, Pulmonary Toxicity: Special Survey
September 6, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 6, 2004
- Sankyo to Drastically Reorganize Branch Offices
September 6, 2004
- Japanese Healthcare Q&A (10)
September 6, 2004
- Zeria Working to Strengthen Product Line-up in GI Field
September 6, 2004
- Profits Up for Top 10 Houses Despite 1.2% Decline in Sales
September 6, 2004
- Hokuyaku to Remain Regional Wholesalers Supporting Regional Med Institutions
September 6, 2004
- 1st Qtr Business Results
September 6, 2004
- Unfair Contracts Still Noted between Wholesalers and Med Institutions: Survey
September 6, 2004
- NEW PRODUCTS
September 6, 2004
- Thinking CRAs Needed: Quintiles Seminar
September 6, 2004
- Daiichi to Strengthen Marketing of Omnipaque in Outpatient Care
September 6, 2004
- BUSINESS NEWS IN BRIEF
September 6, 2004
- Norvasc Was Japan's Top-selling Drug in April-June: IMS Japan
September 6, 2004
- Amended GMP GL at the Final Stage of Preparation
September 6, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 6, 2004
- Korosho's FY2005 Draft Budget Request Reaches \21.26 Trillion
September 6, 2004
- MEDICAL DEVICE NEWS IN BRIEF
September 6, 2004
- METI's FY2005 Draft Budget Request Seeks 14.8% Increase
September 6, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…